Search
Impact of KRASᴳ¹² mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial.
Tabernero J, Taieb J, Fakih M, et al. ESMO Open. 2024;9(3):102945
Efficacy and safety of trifluridine/tipiracil-containing combinations in colorectal cancer and other advanced solid tumors: A systematic review
Shitara K, Falcone A, Fakih MG, et al. The Oncologist. 2024;29(5):e601-e615.
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer
Prager GW, Julien Taieb, Fakih M, et al. Future Oncology. 2024:1-10.
Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
Yoshino T, Julien Taieb, Kuboki Y, et al. Therapeutic Advances in Medical Oncology. 2023;15
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial
Ghidini M, Hochster H, Doi T, et al. Gastric Cancer. 2023;26(4):626-637.
Trifluridine–Tipiracil and Bevacizumab in refractory metastatic colorectal cancer
Prager GW, Taieb J, Fakih M, et al. N Engl J Med. 2023;388(18):1657–1667.
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)
Shitara K, George B, Taieb J, et al. Journal of Cancer Research and Clinical Oncology. 2023;149(11):9361-9374.
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
Shitara K, Doi T, Hosaka H, et al. Gastric Cancer Association. 2022;25(3):586-597.
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
Van Cutsem E, Hochster H, Shitara K, et al. ESMO Open. 2022;7(6):100633.
Trifluridine/Tipiracil and Regorafenib in patients with metastatic colorectal cancer: A retrospective study at a tertiary oncology center
Patel AK, Abhyankar R, Brais LK, et al. The Oncologist. 2021;26(12):e2161-e2169.